StockData
Immunic, Inc. logo

Immunic, Inc. (IMUX) stock

IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$7.52+0.19 (+2.59%)

Close on Nov 18, 2026Market cap $102.61MP/E –Yield 0.00%

Immunic net income

Net income is the profit left for shareholders after every expense, interest and tax.

Immunic's net income for the twelve months ending Jun 30, 2026 was -$111.57M. For fiscal 2025 it was -$97.17M. The highest annual figure on record is -$6.70M in fiscal 2012.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$97.17M–
FY2024Dec 31, 2024-$100.51M–
FY2023Dec 31, 2023-$93.61M–
FY2022Dec 31, 2022-$120.41M–
FY2021Dec 31, 2021-$92.95M–
FY2020Dec 31, 2020-$44.02M–
FY2019Dec 31, 2019-$34.93M–
FY2018Dec 31, 2018-$11.54M–
FY2017Dec 31, 2017-$52.08M–
FY2016Dec 31, 2016-$40.97M–
FY2015Dec 31, 2015-$52.02M–
FY2014Dec 31, 2014-$47.67M–
FY2013Dec 31, 2013-$32.72M–
FY2012Dec 31, 2012-$6.70M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$34.10M–
Q1 FY2026Mar 31, 2026-$32.59M–
Q4 FY2025Dec 31, 2025-$19.30M–
Q3 FY2025Sep 30, 2025-$25.58M–
Q2 FY2025Jun 30, 2025-$26.82M–
Q1 FY2025Mar 31, 2025-$25.47M–
Q4 FY2024Dec 31, 2024-$25.18M–
Q3 FY2024Sep 30, 2024-$24.37M–
Q2 FY2024Jun 30, 2024-$21.38M–
Q1 FY2024Mar 31, 2024-$29.58M–
Q4 FY2023Dec 31, 2023-$21.57M–
Q3 FY2023Sep 30, 2023-$22.77M–
Q2 FY2023Jun 30, 2023-$24.00M–
Q1 FY2023Mar 31, 2023-$25.27M–
Q4 FY2022Dec 31, 2022-$56.47M–
Q3 FY2022Sep 30, 2022-$21.22M–
Q2 FY2022Jun 30, 2022-$21.90M–
Q1 FY2022Mar 31, 2022-$20.81M–
Q4 FY2021Dec 31, 2021-$21.19M–
Q3 FY2021Sep 30, 2021-$19.29M–
Q2 FY2021Jun 30, 2021-$17.93M–
Q1 FY2021Mar 31, 2021-$34.53M–
Q4 FY2020Dec 31, 2020-$11.16M–
Q3 FY2020Sep 30, 2020-$12.91M–
Q2 FY2020Jun 30, 2020-$11.46M–
Q1 FY2020Mar 31, 2020-$8.49M–
Q4 FY2019Dec 31, 2019-$7.69M–
Q3 FY2019Sep 30, 2019-$8.22M–
Q2 FY2019Jun 30, 2019-$14.71M–
Q1 FY2019Mar 31, 2019-$4.31M–
Q4 FY2018Dec 31, 2018-$4.81M–
Q3 FY2018Sep 30, 2018-$1.80M–
Q2 FY2018Jun 30, 2018-$2.67M–
Q1 FY2018Mar 31, 2018-$2.26M–
Q4 FY2017Dec 31, 2017-$14.59M–
Q3 FY2017Sep 30, 2017-$12.48M–
Q2 FY2017Jun 30, 2017-$12.41M–
Q1 FY2017Mar 31, 2017-$12.60M–
Q4 FY2016Dec 31, 2016-$11.73M–
Q3 FY2016Sep 30, 2016-$10.18M–

More Immunic figures

See a number that looks wrong?